Successful Treatment of Chronic Hepatitis C using Pegylated Interferon and Ribavirin in a Patient with Sheehan's Syndrome
Journal Title: International Journal of Virology and AIDS - Year 2016, Vol 3, Issue 2
Abstract
A 50-year-old female with Sheehan's syndrome was treated for chronic hepatitis C using pegylated interferon-α2b and ribavirin. The patient's HCV-RNA status was negative by the fourth week and remained undetectable until the completion of treatment without signs that Sheehan's syndrome had been exaggerated. This case demonstrates that pegylated interferon-α2b and ribavirin does not necessarily exacerbate Sheehan's syndrome.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP354586
- DOI 10.23937/2469-567X/1510028
- Views 148
- Downloads 0
Sensitive, Subtype Independent HIV-1 PCR Assays for Assessment of Residual Viremia and Total HIV-1 DNA
Background Correct measurements of residual viremia and reservoir size are crucial in HIV-1 eradication trials and there is a need for sensitive and automated assays. The increasing worldwide diversity of HIV-1 subtypes...
The AIDS Myth at 30
In 1985 the KGB and East Berlin's professor of Biology started the AIDS disinformation campaign by accusing the United States of America of having constructed and spread the AIDS agent in the course of biological weapons...
Successful Treatment of Chronic Hepatitis C using Pegylated Interferon and Ribavirin in a Patient with Sheehan's Syndrome
A 50-year-old female with Sheehan's syndrome was treated for chronic hepatitis C using pegylated interferon-α2b and ribavirin. The patient's HCV-RNA status was negative by the fourth week and remained undetectable until...
Survival among Dually Infected HIV Patients Compared to HIV-1 Mono-Infected Patients Receiving ART in Senegal: A Twelve-Year Cohort Study
In West Africa, HIV-2 single infection (HIV-2s) and HIV-1 + HIV-2 dual infection (HIV-D) remain endemic but their morbidity is progressively decreasing. Among HIV-D infected patients receiving antiretroviral therapy (ART...
PrEP Works, But Only When You [Have Access to] Take it: Improving PrEP Access for Young People in Chicago and Philadelphia
The 2012 United States Food and Drug Administration approval of Tenofovir/Emtricitabine for HIV pre-exposure prophylaxis (PrEP) has added a highly effective, safe biomedical option to the HIV prevention toolbox. In the U...